In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Oncoimmunology

• Publication date

  2018-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/2162402X.2018.1424673PMID 29721386PMCID PMC5927529
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study

  2017cited by this paper
• Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment

  2017cited by this paper
• Cellular immunotherapies for cancer

  2017cited by this paper
• Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

  2016cited by this paper
• Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients

  2016cited by this paper
• Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy

  2016cited by this paper
• Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases

  2015cited by this paper
• Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.

  2015cited by this paper
• Advances in clinical NK cell studies: Donor selection, manufacturing and quality control

  2015cited by this paper
• Overexpression of CD85j in TNBC patients inhibits Cetuximab‐mediated NK‐cell ADCC but can be restored with CD85j functional blockade

  2015cited by this paper
• Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab

  2015cited by this paper
• Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use

  2015cited by this paper
• NK cells in therapy of cancer.

  2014cited by this paper
• Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

  2014cited by this paper
• The metabolic checkpoint kinase mTOR is essential for interleukin-15 signaling during NK cell development and activation

  2014cited by this paper
• IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.

  2014cited by this paper
• Cancer Immunology at the Crossroads: Experimental Immunotherapies Killer Immunoglobulin-like Receptors and Tumor Immunity

  2014cited by this paper
• KIR and KIR ligand polymorphism: a new area for clinical applications?

  2013cited by this paper
• Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

  2013cited by this paper
• Antibody Therapeutics in Cancer

  2013cited by this paper
• Therapeutic applications: natural killer cells in the clinic.

  2013cited by this paper
• A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.

  2012cited by this paper
• Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.

  2012cited by this paper
• A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

  2011cited by this paper
• Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression

  2011cited by this paper
• T cell exhaustion

  2011cited by this paper
• Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.

  2011cited by this paper
• Allogeneic natural killer cells for refractory lymphoma

  2010cited by this paper
• Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

  2010cited by this paper
• NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

  2010cited by this paper
• Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma

  2009cited by this paper
• Functions of natural killer cells

  2008cited by this paper
• Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy1

  2008cited by this paper
• Programmed death-1 (PD-1) defines a transient and dysfunctional oligoclonal T cell population in acute homeostatic proliferation

  2007cited by this paper
• Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

  2005influential reference
• Indium–111-Labelled Donor-Lymphocyte Infusion by way of Hepatic Artery and Radio-Frequency Ablation against Liver Metastases of Renal and Colon Carcinoma after Allogeneic Hematopoietic Stem-Cell Transplantation

  2004cited by this paper
• Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation

  2004cited by this paper
• NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs.

  2004cited by this paper
• Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming

  2004cited by this paper
• Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming.

  2004cited by this paper
• Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants

  2002cited by this paper
• Feasibility of the Adoptive Transfusion of Allogenic Human Leukocyte Antigen-Matched Natural Killer Cells in Patients With Renal Cell Carcinoma

  2000cited by this paper
• Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB

  1999cited by this paper
• Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB.

  1999cited by this paper
• Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.

  1995cited by this paper
• Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma

  1993cited by this paper
• Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

  1985cited by this paper

• Immunotherapy using allogenic NK cells downregulates mitochondrial-related genes and inhibits the OXPHOS system of malignant meningioma.

  2025cites this paper
• Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles.

  2024cites this paper
• Development of NK cell-based cancer immunotherapies through receptor engineering

  2024cites this paper
• Contribution of natural killer cells in innate immunity against colorectal cancer

  2023cites this paper
• Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy

  2023cites this paper
• Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom

  2023cites this paper
• Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells

  2022cites this paper
• Harnessing NK Cells to Control Metastasis

  2022cites this paper
• Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

  2022cites this paper
• The soldiers needed to be awakened: Tumor-infiltrating immune cells

  2022cites this paper
• NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis

  2022influential citation
• Efficacy and Safety of Cellular Immunotherapy by Local Infusion for Liver Tumor: A Systematic Review and Meta-Analysis

  2022cites this paper
• The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies

  2021cites this paper
• Natural Killer cells and monoclonal antibodies: two partners for successful antibody dependent cytotoxicity against tumor cells.

  2021cites this paper
• Challenges for NK cell-based therapies: What can we learn from lymph nodes?

  2021cites this paper
• Current progress in NK cell biology and NK cell-based cancer immunotherapy

  2020cites this paper
• Recent Progress in the Synergistic Combination of Nanoparticle‐Mediated Hyperthermia and Immunotherapy for Treatment of Cancer

  2020cites this paper
• Manufacturing of natural killer cells for treating solid malignancies

  2020cites this paper
• Combinatorial Immunotherapies for Metastatic Colorectal Cancer

  2020cites this paper
• Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer

  2020cites this paper
• DNT Cell-based Immunotherapy: Progress and Applications

  2020cites this paper
• T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?

  2020cites this paper
• Natural killer cells and cancer therapy, what we know and where we are going.

  2019cites this paper
• Technical advances in NK cell-based cellular immunotherapy

  2019cites this paper
• The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy

  2019cites this paper
• Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer

  2019cites this paper
• Natural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects

  2019cites this paper
• Lactate-Mediated Acidification of Tumor Microenvironment Induces Apoptosis of Liver-Resident NK Cells in Colorectal Liver Metastasis

  2018cites this paper
• NK Cell-Based Immunotherapy in Cancer Metastasis

  2018cites this paper
• ResearchImmunology—Review Natural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects

  year unknowncites this paper